Thrombosis最新文献_第3页

The role of thrombophilia in pregnancy. 血栓在妊娠中的作用。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-12-18 DOI: 10.1155/2013/516420

Elisabeth M Battinelli, Ariela Marshall, Jean M Connors

引用次数: 68

Venous thromboembolism in critically ill cirrhotic patients: practices of prophylaxis and incidence. 重症肝硬化患者的静脉血栓栓塞:预防和发病率的实践。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-12-10 DOI: 10.1155/2013/807526

Hasan M Al-Dorzi, Hani M Tamim, Abdulaziz S Aldawood, Yaseen M Arabi

{"title":"Venous thromboembolism in critically ill cirrhotic patients: practices of prophylaxis and incidence.","authors":"Hasan M Al-Dorzi, Hani M Tamim, Abdulaziz S Aldawood, Yaseen M Arabi","doi":"10.1155/2013/807526","DOIUrl":"https://doi.org/10.1155/2013/807526","url":null,"abstract":"Objectives. We compared venous thromboembolism (VTE) prophylaxis practices and incidence in critically ill cirrhotic versus noncirrhotic patients and evaluated cirrhosis as a VTE risk factor. Methods. A cohort of 798 critically ill patients followed for the development of clinically detected VTE were categorized according to the diagnosis of cirrhosis. VTE prophylaxis practices and incidence were compared. Results. Seventy-five (9.4%) patients had cirrhosis with significantly higher INR (2.2 ± 0.9 versus 1.3 ± 0.6, P < 0.0001), lower platelet counts (115,000 ± 90,000 versus 258,000 ± 155,000/ μ L, P < 0.0001), and higher creatinine compared to noncirrhotic patients. Among cirrhotics, 31 patients received only mechanical prophylaxis, 24 received pharmacologic prophylaxis, and 20 did not have any prophylaxis. Cirrhotic patients were less likely to receive pharmacologic prophylaxis (odds ratio, 0.08; 95% confidence interval (CI), 0.04-0.14). VTE occurred in only two (2.7%) cirrhotic patients compared to 7.6% in noncirrhotic patients (P = 0.11). The incidence rate was 2.2 events per 1000 patient-ICU days for cirrhotic patients and 3.6 events per 1000 patient-ICU days for noncirrhotics (incidence rate ratio, 0.61; 95% CI, 0.15-2.52). On multivariate Cox regression analysis, cirrhosis was not associated with VTE risk (hazard ratio, 0.40; 95% CI, 0.10-1.67). Conclusions. In critically ill cirrhotic patients, VTE incidence did not statistically differ from that in noncirrhotic patients. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"807526"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31996605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Postoperative venous thromboembolism prophylaxis by general surgeons in a developing country: a survey. 发展中国家普外科医生术后静脉血栓栓塞预防:一项调查

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-09-19 DOI: 10.1155/2013/873750

Aniketh Venkataram, Shivashankar Santhosh, Deevish Dinakar, Shivananda Siddappa, Rajashekara Babu, Sadashivaiah Shivaswamy

{"title":"Postoperative venous thromboembolism prophylaxis by general surgeons in a developing country: a survey.","authors":"Aniketh Venkataram, Shivashankar Santhosh, Deevish Dinakar, Shivananda Siddappa, Rajashekara Babu, Sadashivaiah Shivaswamy","doi":"10.1155/2013/873750","DOIUrl":"https://doi.org/10.1155/2013/873750","url":null,"abstract":"Venous thromboembolism (VTE) is the most common preventable cause of hospital death. Several audits in the west have demonstrated that appropriate thromboprophylaxis is not being offered to a large number of surgical patients. Similar audits are lacking in the Indian population, and a perception exists among Indian surgeons that Indian patients are not susceptible to VTE. Hence we undertook a survey to analyze the existing knowledge and practice of VTE prophylaxis amongst general surgeons in India. A questionnaire-based survey was conducted on 100 active general surgeons. We found that 97% of surgeons had encountered VTE in their practice, and 49% had encountered mortality from pulmonary embolism. 64% of surgeons do not routinely score patients preoperatively for their VTE risk, and only 33% reported the presence of an institute-based protocol for the same. There was a wide disparity in the prophylaxis methods used for each risk group, particularly in the moderate-risk group. These findings suggest the need for adoption of institute-based protocols for prophylaxis and the evolution of Indian guidelines for VTE prophylaxis. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"873750"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/873750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31868151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis. 骨水泥全髋关节置换术中凝血和纤溶的生物标志物与术后开始血栓预防的比较。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-12-16 DOI: 10.1155/2013/563217

Pål O Borgen, Ola E Dahl, Olav Reikeras

{"title":"Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis.","authors":"Pål O Borgen, Ola E Dahl, Olav Reikeras","doi":"10.1155/2013/563217","DOIUrl":"https://doi.org/10.1155/2013/563217","url":null,"abstract":"Venous thrombosis is common in elective hip surgery, and prophylaxis is recommended. Clinical trials suggest that the drug dose and timing of initiating prophylaxis significantly influence antithrombotic effectiveness and safety. We studied the time course and gradient of plasma coagulation and fibrinolysis during total hip arthroplasty (THA) in twenty patients that were randomly assigned to have the first dose of 5000 IU dalteparin subcutaneously (sc) injected 12 hours before or 6 hours after surgery. Baseline characteristics were similar in both groups. Specific biomarkers on coagulation (prothrombin fragment 1+2 (F1+2)) and fibrinolytic activity (plasmin/ α 2-antiplasmin complex (PAP) and D-dimer) were collected at six events during hospitalization and analysed. There were no significant group differences in the biomarkers at any time point. The highest concentrations were measured 6 hours after surgery and before the first postoperative injection. A marked decrease followed at the first postoperative day, and then a second increase in plasma concentrations was observed 6 days after surgery. This study showed that activation of coagulation and fibrinolysis by the operative trauma was the same when the first dose of dalteparin was injected 12 hours before or 6 hours after surgery. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"563217"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32054036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry. 中风后心房颤动患者口服抗凝疗法的使用情况：一项全国性登记的结果。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-11-17 DOI: 10.1155/2013/601450

Stine Funder Jespersen, Louisa M Christensen, Anders Christensen, Hanne Christensen

{"title":"Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry.","authors":"Stine Funder Jespersen, Louisa M Christensen, Anders Christensen, Hanne Christensen","doi":"10.1155/2013/601450","DOIUrl":"10.1155/2013/601450","url":null,"abstract":"Background. The knowledge is still sparse about patient related factors, influencing oral anticoagulation therapy (OAC) rates, in stroke patients with atrial fibrillation (AF). Aims. To assess the use of OAC in ischemic stroke patients diagnosed with AF and to identify patient related factors influencing the initiation of OAC. Methods. In the nationwide Danish Stroke Registry we identified 55,551 patients admitted with acute ischemic stroke from 2003 to 2011. Frequency analysis was used to assess the use of OAC in patients with AF, and logistic regression was used to determine independent predictors of OAC. Results. 17.1% (n = 9,482) of ischemic stroke patients had AF. OAC prescription rates were increasing, and in 2011 46.6% were prescribed OAC, 42.5% had a contraindication, and 3.7% were not prescribed OAC without a stated contraindication. Younger age, less severe stroke, and male gender were positive predictors of OAC, while excessive alcohol consumption, smoking, and institutionalization were negative predictors of OAC (P values < 0.05). Conclusions. Advanced age, severe stroke, female gender, institutionalization, smoking, and excessive alcohol consumption were associated with lower OAC rates. Contraindications were generally present in patients not in therapy, and the assumed underuse of OAC may be overestimated. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"601450"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31965096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. 新型口服抗凝剂治疗肺栓塞:疗效、出血风险和监测。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-04-10 DOI: 10.1155/2013/973710

Kelly M Rudd, Elizabeth Lisa M Phillips

引用次数: 19

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. 达比加群、利伐沙班或阿哌沙班与华法林对非瓣膜性心房颤动患者的影响:一项系统综述和亚组荟萃分析

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-12-22 DOI: 10.1155/2013/640723

Antonio Gómez-Outes, Ana Isabel Terleira-Fernández, Gonzalo Calvo-Rojas, M Luisa Suárez-Gea, Emilio Vargas-Castrillón

{"title":"Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups.","authors":"Antonio Gómez-Outes, Ana Isabel Terleira-Fernández, Gonzalo Calvo-Rojas, M Luisa Suárez-Gea, Emilio Vargas-Castrillón","doi":"10.1155/2013/640723","DOIUrl":"https://doi.org/10.1155/2013/640723","url":null,"abstract":"Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation (NVAF). Methods. MEDLINE and CENTRAL, regulatory agencies websites, clinical trials registers and conference proceedings were searched to identify randomised controlled trials of NOAC versus warfarin in NVAF. Two investigators reviewed all studies and extracted data on patient and study characteristics along with cardiovascular outcomes. Relative risks (RR) and 95% confidence intervals (CI) were estimated using a random effect meta-analysis. Results. Three clinical trials in 50,578 patients were included. The risk of non-hemorrhagic stroke and systemic embolic events (SEE) was similar with the NOAC and warfarin (RR = 0.93; 95% CI = 0.83-1.04), while the risk of intracranial bleeding (ICB) with the NOAC was lower than with warfarin (RR = 0.46; 95% CI = 0.33-0.65). We found differences in the effect size on all strokes and SEE depending on geographic region as well as on non-hemorrhagic stroke, SEE, bleeding and mortality depending on time in therapeutic range. Conclusion. The NOAC seem no more effective than warfarin for prevention of nonhemorrhagic stroke and SEE in the overall NVAF population, but are generally associated with a lower risk of ICB than warfarin. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"640723"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/640723","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32054037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 173

Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. 预防和治疗静脉血栓栓塞与新的口服抗凝剂:临床医生的实用更新。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-02-21 DOI: 10.1155/2013/183616

Nay Min Tun, Thein Hlaing Oo

引用次数: 15

Regulation of vascular function on posttranscriptional level. 在转录后水平上调控血管功能。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-10-31 DOI: 10.1155/2013/948765

Andreas Eisenreich

引用次数: 17

A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis. 残余静脉阻塞研究在原发性和继发性静脉血栓中的实用性系统回顾。

Thrombosis Pub Date : 2013-01-01 Epub Date: 2013-11-19 DOI: 10.1155/2013/247913

Murali Janakiram, Matthew Sullivan, Marina Shcherba, Shuang Guo, Henny H Billett

{"title":"A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.","authors":"Murali Janakiram, Matthew Sullivan, Marina Shcherba, Shuang Guo, Henny H Billett","doi":"10.1155/2013/247913","DOIUrl":"10.1155/2013/247913","url":null,"abstract":"Background. Residual vein obstruction (RVO), the persistence of venous thrombosis with time and often after anticoagulation, may indicate a systemic prothrombotic condition. Prior studies have shown varying efficacy in using RVO as a risk factor for future venous thromboembolic (VTE) recurrence. Methods. To assess whether positive RVO imaging predicts recurrent VTE events, we performed a meta-analysis on studies in which patients with documented VTEs, anticoagulated for a minimum of 4 weeks, had repeat sonography to assess RVO and were subsequently followed for recurrent events. Results. Thirteen studies met inclusion criteria: 3531 patient VTE events with 3474 evaluable results were analyzed. The presence of RVO was associated with recurrence in all VTE (OR 1.93; 95% CI: 1.29, 2.89) and secondary VTE (OR 2.78; 95% CI: 1.41, 5.5) but not for primary VTE (OR 1.35; 95% CI: 0.87, 2.08). When cancer patients were eliminated from the secondary VTE group, there was no longer a significant association of RVO with VTE recurrence (OR 1.73; 95% CI: 0.81, 3.67) while in the subset of cancer patients, presence of RVO was associated with an increase in VTE recurrence risk (OR 5.14; 95% CI: 1.59, 16.65, P < 0.006). Conclusions. We conclude that the presence of RVO is associated with recurrence in secondary VTE but not in primary VTE and that association may be driven by the subset with cancer. ","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2013 ","pages":"247913"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31965153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0